###begin article-title 0
###xml 73 102 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 634 637 634 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink">FL4</sub>
###xml 0 29 <span type="species:ncbi:11673">Feline immunodeficiency virus</span>
###xml 31 34 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 383 386 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 423 426 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 468 471 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 512 515 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 730 733 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 771 774 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 779 782 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 884 887 <span type="species:ncbi:11673?1.0">FIV</span>
Feline immunodeficiency virus (FIV) targets helper T cells by attachment of the envelope glycoprotein (Env) to CD134, a subsequent interaction with CXCR4 then facilitating the process of viral entry. As the CXCR4 binding site is not exposed until CD134-binding has occurred then the virus is protected from neutralising antibodies targeting the CXCR4-binding site on Env. Prototypic FIV vaccines based on the FL4 strain of FIV contain a cell culture-adapted strain of FIV Petaluma, a CD134-independent strain of FIV that interacts directly with CXCR4. In addition to a characteristic increase in charge in the V3 loop homologue of FIVFL4, we identified two mutations in potential sites for N-linked glycosylation in the region of FIV Env analogous to the V1-V2 region of HIV and SIV Env, T271I and N342Y. When these mutations were introduced into the primary GL8 and CPG41 strains of FIV, the T271I mutation was found to alter the nature of the virus-CD134 interaction; primary viruses carrying the T271I mutation no longer required determinants in cysteine-rich domain (CRD) 2 of CD134 for viral entry. The T271I mutation did not confer CD134-independent infection upon GL8 or CPG41, nor did it increase the affinity of the CXCR4 interaction, suggesting that the principal effect was targeted at reducing the complexity of the Env-CD134 interaction.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 443 444 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 909 910 909 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1251 1252 1251 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1387 1388 1387 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1389 1390 1389 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1478 1479 1478 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1782 1784 1782 1784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 116 121 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1014 1019 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1674 1677 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1687 1695 <span type="species:ncbi:9606">patients</span>
The initial event in the process of viral entry is the interaction between the virus and its cellular receptor. For HIV-1, the trimeric Env complex comprising gp120 and gp41 attaches to the primary viral receptor CD4 [1,2] on the surface of the target cell. This interaction is believed to induce a conformational change in gp120 that leads to exposure of the binding site for the coreceptor, usually the chemokine receptors CXCR4 and CCR5 [3,4]. Engagement of the coreceptor triggers a further conformational change in the Env complex that results in exposure of the gp41 fusion domain and initiates the process of fusion of the viral and cellular membranes. Given that the virus-receptor interaction initiates the process of viral entry, the binding sites on gp120 for the primary and co-receptors should, logically, make good targets for neutralising antibodies. Indeed, the monoclonal antibody (MAb) b12 [5] targets the CD4 binding site on gp120 and has broad neutralising activity against diverse isolates of HIV-1 while MAbs such as 17b, target the chemokine receptor binding site, engaging the Env complex post-attachment to CD4 (a "CD4-induced" epitope). During natural infection antibodies targeting the CD4 binding site are seldom elicited [6]; the CD4 binding site is recessed in gp120, partially occluded by the hypervariable loops and protected by "conformational masking" [7-9]. When such antibodies are elicited, they display potent, broad neutralizing activity [6]. In contrast, although the co-receptor binding site is not exposed on the virion until after CD4 binding has occurred, antibodies targeting the co-receptor binding site are common in sera from HIV-infected patients, and in the presence of soluble CD4 display potent cross-clade neutralising activity [10].
###end p 4
###begin p 5
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 474 481 474 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 541 548 541 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 765 767 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 768 770 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 945 947 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1362 1364 1354 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1513 1515 1505 1507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 16 19 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 24 27 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 818 821 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 878 883 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1212 1217 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1276 1281 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Some strains of HIV and SIV are capable of by-passing the primary receptor and interacting directly with the co-receptor [11-15]. In these "CD4-independent" strains of virus, the chemokine receptor binding site may be more exposed [16] and as such, they may be more sensitive to neutralising antibodies than their CD4-dependent counterparts [11,16-19]. Accordingly, the humoral immune response may exert a strong selective pressure against the emergence of CD4-independence in vivo: CD4-independent strains would have a broader cell tropism in vivo, assisting with viral dissemination into cellular compartments where CD4 expression may be low, for example the CNS [20-22]. The inextricable link between receptor usage, cell tropism and neutralisation sensitivity [23,24] may advise the design of novel immunogens for HIV vaccination. Deletion of the V2 hypervariable loop from HIV-1 SF162 renders the virus susceptible to virus neutralisation [25]. Antibodies raised against the SF162DeltaV2 immunogen target the CD4-binding site preferentially suggesting that the V2 loop deletion exposes the CD4-binding site. The V2-loop deletion in SF162DeltaV2 eliminates a site for N-linked glycosylation and studies with HIV-1 ADA have shown that loss of a single N-linked glycan from HIV-1 ADA gp120 switches the virus from a CD4-dependent to CD4-independent phenotype [12] by re-positioning the V1/V2 loops. Similarly, mutation of glycosylation sites in SIVmac239 Env enhance CD4-independent infection mediated by CCR5 [26]. Taken together, these data indicate it may be possible to manipulate the humoral immune response towards the CD4 binding site by modulating the surrounding environment on gp120 and in doing so, create an immunogen that will induce broadly neutralising antibodies.
###end p 5
###begin p 6
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 637 639 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 0 29 <span type="species:ncbi:11673">Feline immunodeficiency virus</span>
###xml 31 34 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 68 80 <span type="species:ncbi:9685">domestic cat</span>
###xml 159 164 <span type="species:ncbi:9606">human</span>
###xml 173 176 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 401 404 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 517 520 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 660 663 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 785 788 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 911 914 <span type="species:ncbi:11673?1.0">FIV</span>
Feline immunodeficiency virus (FIV) is a widespread pathogen of the domestic cat and in its natural host species it induces a disease state similar to AIDS in human beings. FIV targets CD4+ helper T cells by binding to CD134 (also known as OX40) [27], a member of the tumour necrosis factor receptor superfamily that is expressed selectively upon feline helper T cells [28,29]. All primary strains of FIV tested to date, utilise CD134 as a receptor for viral entry [27,29,30], however cell culture-adapted strains of FIV such as Petaluma F14 and 34TF10 [31,32] are able to infect and form syncytia in cell lines in the absence of CD134 [27]. CD134-independent FIV infection is mediated by a direct interaction with CXCR4 [33,34], analogous to infection with CD4-independent strains of HIV [13]. However, over-expression of CXCR4 alone is sufficient to render cells susceptible to infection with some strains of FIV [35], suggesting that such strains of virus may have a propensity to adaptation in cell culture to CD134-independence.
###end p 6
###begin p 7
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1595 1597 1595 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1598 1600 1598 1600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 127 130 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 365 368 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 388 391 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 799 802 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1310 1313 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1410 1413 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1582 1585 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1590 1593 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
Whole inactivated virus vaccines derived from the FL4 cell line (a cell line infected persistently with the Petaluma strain of FIV [36]) induce both humoral and cellular immunity and offer a degree of protection against challenge with heterologous strains of virus [37-42]. Accordingly, the FL4 cell line has provided the basis for the first commercially available FIV vaccine (Fel-O-Vax FIV, Fort Dodge), approved for use in the USA, Japan, New Zealand and Australia. The vaccine has attracted a degree of controversy as independent experiments have failed to demonstrate protective efficacy against heterologous challenge [43], addressing these conflicting reports is of importance to advancing lentiviral vaccine development [44]. Previously, Env-based immunogens derived from primary strains of FIV failed to induce protective immunity, and in some cases led to an accelerated viraemia following challenge [45-51]. In order to inform the design of lentiviral vaccines that will induce broadly neutralising antibodies, we examined the FL4 virus for the presence of novel features acquired during the process of adaptation to cell culture that may have contributed to its enhanced immunogenicity. Here, we identify a potential site for N-linked glycosylation that is highly conserved among field isolates of FIV but which is absent from the FL4 Env. By introducing similar mutations into primary isolates of FIV, we demonstrate that N-linked glycosylation at this site impacts on the virus-receptor interaction. These findings bear striking similarities to observations with both HIV and SIV [52-57] and may provide an insight into the mechanism by which the FL4 immunogen induces virus neutralising antibodies.
###end p 7
###begin title 8
Methods
###end title 8
###begin title 9
DNA constructs and mutagenesis
###end title 9
###begin p 10
###xml 780 784 780 784 <sub xmlns:xlink="http://www.w3.org/1999/xlink">MYA </sub>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1129 1133 1129 1131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 18 21 <span type="species:ncbi:11673?1.0">FIV</span>
The FL4 strain of FIV lacks sites for N-linked glycosylation at Asn-269 due to a threonine to isoleucine switch at 271 (T271I), and Asn-342 due to an asparagine to tyrosine substitution at 342 (N342Y). We mutated these sites in the GL8 and CPG41 Envs by amplification using a 5' primer from the leader-SU junction 5-TAGACGCGTAAGATTTTTAAGGTATTC (5' MLU) and either 5'-CGAGATATTATAACAGATGTTATTAGCACAT-3' (ENV 7076) or 5' GGTCTTGAATCTGTGAAGTGTACCACATA (ENV 7288). The amplification products were purified by agarose gel electrophoresis (QIAEx gel extraction kit, QIAGen, UK) and used as 5' primer in conjunction with a 3' primer from the RRE region 5'-AATGGATTCATATGACACATCTTCCTCAAAGGG (3' NDE) to amplify the full-length SU-TM products. The mutated Envs were sub-cloned into the GL8MYA molecular clone as Mlu-I/Nde-I fragments as previous [58]. The double mutant (Asn-269 and Asn-342) was generated by amplification firstly using 5'MLU and ENV-7076, extending using ENV-7288 and then finally amplifying the entire Env using the double-mutated fragment and 3'NDE primer. The sequences of each construct were confirmed using a BigDye(R) Terminator v1.1 cycle sequencing kit (Applied Biosystems) followed by analysis on an Applied Biosystems 3700 genetic analyser.
###end p 10
###begin title 11
Cells and viruses
###end title 11
###begin p 12
###xml 7 9 7 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 26 28 26 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 201 207 <span type="species:ncbi:9913">bovine</span>
###xml 386 392 <span type="species:ncbi:10090">murine</span>
###xml 429 434 <span type="species:ncbi:9606">human</span>
###xml 571 576 <span type="species:ncbi:9606">human</span>
MYA-1 [59] cells and MCC [60]-derived cell lines were cultured in RPMI 1640 medium. 293T were maintained in Dulbeccos modification of Eagle's medium (DMEM). All media were supplemented with 10% foetal bovine serum (FBS), 2 mM glutamine, 0.11 mg/ml sodium pyruvate 100 IU/ml penicillin, 100 mug/ml streptomycin. The medium for MYA-1 cells was supplemented with conditioned medium from a murine cell line (L2.3) transfected with a human IL-2 expression construct (kind gift of M. Hattori, University of Tokyo) at a final concentration equivalent to 100 U/ml of recombinant human interleukin-2 (IL-2), and 50 muM 2-mercaptoethanol. All media and supplements were obtained from InVitrogen Life Technologies Ltd. (Paisley, UK). Cell lines expressing CD134 and the chimaeric constructs were maintained in G418 (InVitrogen, Paisley, UK).
###end p 12
###begin p 13
Molecular clones carrying the Asn-269 (T271I), Asn-342 (N342Y) or the Asn-269/Asn-342 double mutant (Delta2N) were transfected into 293T cells using Superfect (QIAGen) and recovered by co-culture with MYA-1 cells at 72 hrs post-transfection. Viruses were expanded in MYA-1 cells before harvesting, 0.45 mum filtration and storage at -80degreesC.
###end p 13
###begin title 14
Polyacrylamide gel electrophoresis (PAGE) analyses
###end title 14
###begin p 15
###xml 15 17 15 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
###xml 437 439 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 584 586 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 747 750 <span type="species:ncbi:9685">cat</span>
###xml 762 765 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 775 779 <span type="species:ncbi:9685">cats</span>
###xml 805 809 <span type="species:ncbi:9925">goat</span>
###xml 815 818 <span type="species:ncbi:9685">cat</span>
###xml 880 884 <span type="species:ncbi:9925">goat</span>
###xml 890 895 <span type="species:ncbi:10090">mouse</span>
1.0 to 1.5 x 107 infected MYA-1 cells were washed by centrifugation (1000 rpm, 5 mins.) through ice-cold phosphate buffered saline and resuspended in lysis buffer comprising 1% CHAPS in 10 mM Tris (ph 7.4), 150 mM sodium chloride, 2 mM ethylenediamine tetraacetic acid and supplemented with a Completetrade mark protease inhibitor tablet (Roche Applied Science, Burgess Hill, UK). Lysates were mixed with reducing Laemmli sample buffer [61] and separated on either 4-15% polyacrylamide gels (Ready-Gel, Biorad, Hemel Hempstead, UK) or 10% polyacrylamide gels (prepared as previously [62]). Separated proteins were transferred to nitrocellulose by electroblotting (iBlottrade mark, Invitrogen); viral antigens were detected using pooled polyclonal cat serum from FIV infected cats followed by biotinylated goat anti-cat IgG, or monoclonal antibody vpg71.2 followed by biotinylated goat anti-mouse IgG conjugates (Vector Laboratories Ltd., Peterborough, UK). Bound conjugate was revealed using the Vectastain ABC kit and 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium substrate (Vector Laboratories Ltd.).
###end p 15
###begin title 16
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 20 23 <span type="species:ncbi:11673?1.0">FIV</span>
Preparation of HIV (FIV) pseudotypes
###end title 16
###begin p 17
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 125 129 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 156 157 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 158 160 156 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 525 527 516 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 0 3 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 299 302 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 303 306 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 320 323 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 342 345 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 713 716 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 718 721 <span type="species:ncbi:11673?1.0">FIV</span>
FIV env gene expression constructs GL8, B2542, CPG41 and PPR have been described previously [27,30,63]. 5 mug of each VR1012-env and 7.5 mug of pNL4-3-Luc-E-R- were co-transfected into HEK-293T cells using SuperFect activated dendrimer (QIAgen) as per manufacturer's instructions. The nomenclature "HIV(FIV)" denotes an FIV Env protein on an HIV particle. Culture supernatants were collected at 48 hours post-transfection, filtered at 0.45 mum and frozen at -80degreesC until required. Target cell lines were seeded at 5 x 104 cells per well of a CulturPlatetrade mark-96 assay plate (Perkin Elmer, Life and Analytical Sciences, Beaconsfield, UK) and used immediately. The cells were then infected with 50 mul of HIV (FIV) luciferase pseudotypes, cultured for 72 hours and then luciferase activity quantified by the addition of 50 mul of Steadylite HTStrade mark (Perkin Elmer) luciferase substrate prior to measurement by single photon counting on a MicroBeta TriLux luminometer (Perkin Elmer).
###end p 17
###begin title 18
Virus neutralisation assays
###end title 18
###begin p 19
###xml 228 230 219 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 127 130 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 131 134 <span type="species:ncbi:11673?1.0">FIV</span>
Sera were diluted 5-fold in MYA-1 culture medium and then 25 mul of each dilution (in triplicate) was incubated with 25 mul of HIV(FIV) luciferase pseudotype, incubated for one hour at 37degreesC and then added to 50 mul (5 x 104 cells) of CLL-CD134 cells per well of a CulturPlatetrade mark-96 assay plate (Perkin Elmer, Life and Analytical Sciences, Beaconsfield, UK). The cells were then cultured for 72 hours and luciferase activity quantified by the addition of 100 mul of Steadylite HTStrade mark (Perkin Elmer) luciferase substrate and measurement by single photon counting on a MicroBeta luminometer (Perkin Elmer).
###end p 19
###begin title 20
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 10 13 <span type="species:ncbi:11673?1.0">FIV</span>
Growth of FIV in vitro
###end title 20
###begin p 21
###xml 18 27 18 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 14 17 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 279 284 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The growth of FIV in vitro was assessed in MYA-1 cells. Supernatants were collected every three days and assayed for reverse transcriptase (RT) activity using Lenti-RT non-isotopic RT assay kit (Cavidi Tech., Uppsala, Sweden). RT values were then calculated relative to purified HIV-1 RT standard.
###end p 21
###begin title 22
Syncytium formation in adherent cells
###end title 22
###begin p 23
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
AH927 cells stably transduced with pDONAI vector only, or with vector encoding fCD134, fCRD1xhCD134 or hCD134, were transfected with each env construct using Superfect (Qiagen, Crawley, UK) and incubated for 48 hours at 37degreesC. The cells were then fixed and stained with 1% methylene blue/0.2% basic fuchsin in methanol and photographed using a Leica DMLB microscope (Leica Microsystems (UK) Ltd., Milton Keynes) and Photometrics SenSys digital camera (Photometrics Ltd., Tucson, USA).
###end p 23
###begin title 24
Inhibition of viral entry
###end title 24
###begin p 25
###xml 6 8 6 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
1 x 105 MYA-1 or CLL-CD134 cells were incubated with the CXCR4 antagonist AMD3100 [64-66] in complete medium in 96-well culture-treated luciferase assay plates (CulturPlatetrade mark 96) for 30 minutes at 37degreesC. Viral pseudotypes were then added and the plate returned to the 37degreesC incubator. Cultures were maintained for 72 hours post-infection at which point 100 mul of Steadylite HTStrade mark (Perkin Elmer) luciferase substrate were added and luminescence measured by single photon counting on a MicroBeta luminometer (Perkin Elmer).
###end p 25
###begin title 26
Production of recombinant IgG-Fc fusion proteins
###end title 26
###begin p 27
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 748 750 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 0 3 <span type="species:ncbi:11673?1.0">FIV</span>
FIV Env SU-Fc fusion proteins were produced by amplifying the SU coding sequence with the oligonucleotide primers 5'-CGATCTAGAAACAATAATTATGGCAGAAG-3' and 5'-GGCGGCCGCTGGTACCAC(C/T)AAGTAATC-3' corresponding to the start codon for Env leader sequence and the SU/TM junction respectively. The amplified products were cloned as XbaI/NotI fragments into pTorsten [67], expressed in CHO cells in CELLine AD1000 bioreactor flasks (Integra Biosciences (Scientific Laboratory Supplies, Nottingham, U.K.)) in medium supplemented with low IgG serum (Integra Biosciences). Culture supernatant was filtered at 0.22 mum and frozen at -80degreesC prior to use in order to preserve optimal bioactivity. Proteins were purified from culture supernatant as previous [28].
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
###xml 20 23 <span type="species:ncbi:11673?1.0">FIV</span>
Characterisation of FIV FL4 SU
###end title 29
###begin p 30
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 1385 1387 1385 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 1430 1432 1430 1432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 1966 1968 1966 1968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1969 1971 1969 1971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1972 1974 1972 1974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 113 116 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 274 277 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 370 373 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 552 555 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1614 1617 <span type="species:ncbi:11673?1.0">FIV</span>
The FL4 cell line is a feline lymphoblastoid cell line that is persistently infected with the Petaluma strain of FIV [68]. The virus derived from FL4 cells provided the substrate for whole inactivated virus vaccines that conferred strain-specific immunity to infection with FIV [37,38,41], and, in combination with the subtype D Shizuoka strain, the basis for Fel-O-Vax FIV (Fort Dodge Animal Health). The predicted amino acid sequence of the FL4 vaccine strain was compared with that of the prototypic F14 and 34TF10 clones of the Petaluma isolate of FIV [31,69] in order to identify non-synonymous mutations in gp120 that may have been acquired during the process of cell culture adaptation. Unique amino acid substitutions in SU were identified at T271I, N342Y, W347R and F388L (amino acid numbering is relative to F14 [31]). Of these substitutions, T271I and N342Y ablated potential sites for N-linked glycosylation in SU. We asked whether the T271I, N342Y substitutions were observed in field isolates by comparing the FL4 sequence with published sequences using the BLAST search program [70]. The potential site for N-linked glycosylation targeted by the N342Y mutation was unique to FL4 (in comparison with 35 published amino acid sequences) while the N-linked glycosylation site targeted by the T271I mutation was absent in only three other sequences (n = 34); Aomori 1 and 2 [71] (two related Japanese isolates) and FC2 [72]. Given that the T271I and N342Y substitutions were uncommon amongst field isolates and present in neither the F14 and 34TF10 molecular clones, nor the parent biological isolate of FIV Petaluma (not shown), we hypothesised that these mutations may have either been acquired during the process of cell culture adaptation, or amplified from an initial quasispecies during cell culture. Similar adaptations have been shown previously to affect receptor usage for lentiviruses and to alter neutralisation sensitivity and immunogenicity [25,52,73].
###end p 30
###begin p 31
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 920 922 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 936 938 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1187 1189 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1190 1192 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 1193 1195 1193 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 1196 1198 1196 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 1294 1296 1294 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 81 84 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 158 161 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 169 172 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 325 328 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 392 395 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 453 456 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 560 563 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 568 571 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 655 658 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 974 977 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1016 1019 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1216 1219 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We next examined the predicted locations of T271I and N342Y substitutions on the FIV SU protein, comparing the locations with schematic structural models for FIV SU and HIV SU based on predictive algorithms for secondary structure [74], disulphide bond architecture [75,75,76] and informed by the solved crystal structure of HIV Env [7,8]. T271I and N342Y are predicted to lie in a region of FIV SU which may be analogous to the area at the base of the HIV V1 and V2 stem (Fig. 1A). For the purpose of this study, and to assist with direct comparisons between FIV and HIV, this region is referred to as the V1/V2 homologue herein. Although this region of FIV Env was thought formerly to be relatively conserved, a reappraisal based on accumulated Env sequence data indicates pockets of variability within this region, as illustrated when variability is plotted using consensus position-specific scoring matrix analysis [77] (PSSM, Fig. 1B). Mutations in the V1/V2 region of HIV SU affect the interaction between the HIV SU and its receptor and co-receptor(s) and alter the antigenicity of the envelope glycoprotein, promoting the production of antibodies targeting the CD4 binding site [12,73,78,79]. Similarly, for HIV loss of N-linked glycans from this region contribute to CD4-independence [12].
###end p 31
###begin p 32
###xml 37 40 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 393 396 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 439 442 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A. Schematic structural model of the FIV SU proteins illustrating the locations of the T271I and N342Y mutations (red), conserved cysteine residues (green) and predicted sites for N-linked glycosylation (). Residues in the V1/V2 or V3 homologues displaying >10% variation from the consensus sequence are shaded. B. Position-specific scoring matrix (PSSM) analysis of amino acids 248 to 445 of FIV SU encompassing the homologous regions to HIV V1/V2 and V3 illustrating the likelihood of the consensus amino acid appearing in an SU sequence. T271 and N342 are arrowed.
###end p 32
###begin title 33
###xml 72 75 <span type="species:ncbi:11673?1.0">FIV</span>
Incorporation of the T271I and N342Y mutations into primary isolates of FIV
###end title 33
###begin p 34
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 736 738 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 841 843 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 69 72 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 522 525 <span type="species:ncbi:11673?1.0">FIV</span>
The T271I and N342Y mutations were reproduced in molecular clones of FIV GL8 and a chimeric molecular clone bearing the CPG41 Env in the GL8 backbone by site-directed mutagenesis. Constructs were transfected into 293T cells and replication competent virus was recovered into IL2-dependent feline T cells (MYA-1). All viruses replicated with similar efficiency in MYA-1 cells (not shown). Bulk supernatants were prepared, virus pelleted by ultracentrifugation and analysed by SDS-PAGE. Immunoblotting using polyclonal anti-FIV (Fig. 2A) confirmed that similar levels of viral proteins were produced by each virus. Although a marginal reduction in the apparent size of Env was suggested in the Delta2N mutants of both GL8 and CPG41 (Fig. 2A), this was visualised more readily when the GL8 viruses were separated on a 10-20% gradient gel (Fig. 2B) and probed with the subtype-specific monoclonal antibody vpg71.2 (vpg71.2 does not recognise CPG41 Env). Under these conditions, a clear downward shift could be discerned in the Delta2N double mutant virus but in neither of the single mutants.
###end p 34
###begin p 35
###xml 327 330 <span type="species:ncbi:9685">cat</span>
###xml 336 339 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 540 543 <span type="species:ncbi:11673?1.0">FIV</span>
Mutant proviral clones bearing T271I or N342Y yield infectious virus. A. Pelleted virus from MYA-1 cells infected with GL8 (1-4) and CPG41 (5-8) viruses bearing WT (1,5), T271I (2,6), N342Y (3,7) or Delta2N (4,8) were separated by reducing SDS-PAGE on a 12% acrylamide gel, transferred to nitrocellulose and probed with pooled cat anti-FIV. Approx. molecular mass (kDa) are on left, primary reactivities Env, prGag and CA arrowed on right. B. 10-20% gradient gel analysis of GL8 WT (1), T271 (2), N342Y (3) and Delta2N (4) probed with anti-FIV (subtype-specific) SU monoclonal antibody vpg71.2. Approx. molecular mass (kDa) on left, Env is arrowed on right.
###end p 35
###begin title 36
Effect of the T271I and N342Y mutations on receptor usage by GL8 and CPG41
###end title 36
###begin p 37
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 894 896 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 913 915 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1090 1092 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1093 1095 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1433 1435 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 0 3 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 259 264 <span type="species:ncbi:9606">human</span>
###xml 596 601 <span type="species:ncbi:9606">human</span>
###xml 672 675 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 677 680 <span type="species:ncbi:11673?1.0">FIV</span>
FIV GL8 and CPG41 require determinants in both CRDs 1 and 2 of CD134 for viral entry while infection with strains such as PPR and B2542 is mediated by CRD1 alone [30,63]. Accordingly, a chimeric CD134 molecule comprising CRD1 of feline CRD1 in the context of human CD134 may be used to differentiate strains such as GL8 and CPG41 from strains such as PPR and B2542 in viral entry assays (reviewed in [80]). The feline cell lines AH927-FX4P [81] (Fig. 3A) and MCC [27] (Fig. 3B) stably expressing full-length feline CD134 (CD134) or a chimeric receptor bearing feline CD134 CRD1 in the context of human CD134 (CRD1), or transduced with vector only (CON) were infected with HIV (FIV) luciferase pseudotypes bearing the wild type (WT), T271I, N342Y or Delta2N Envs derived from GL8 and CPG41 and viral entry was assessed. Pseudotypes bearing either the WT or mutant Envs infected AH927-FX4P (Fig. 3A.) and MCC (Fig. 3B.) cells expressing CD134 with comparable efficiency. Infection of CRD1-expressing cells was diminished greatly for both GL8 and CPG41 WT Envs, consistent with previous data [30,63]. The N342Y mutants behaved ostensibly the same as the WT Envs, demonstrating a marked preference for CD134 over the CRD1 chimera. In contrast, introduction of the T271I and Delta2N Envs partially restored the ability of the viruses to use the CRD1 chimera (significant enhancement, t-test). The effect was most stark on MCC cells (Fig. 3B.) where GL8 WT infection of MCC-CRD1 was 300-fold less efficient, whereas infection with the T271I and Delta2N mutants was reduced by only 27 and 47-fold respectively, suggesting that the presence of the T271I mutation, but not the N342Y mutation, facilitated the interaction between the GL8 Env and CRD1 of CD134.
###end p 37
###begin p 38
###xml 47 49 47 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 613 618 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">envs </italic>
###xml 502 507 <span type="species:ncbi:9606">human</span>
Infection of the feline cell lines AH927-FX4P [81] (A) and MCC [27] (B) stably-transduced with retroviral vectors encoding full-length fCD134 (CD134), CRD1 of fCD134 in the context of hCD134 (CRD1) or vector only control (CON). Infection of both cell lines expressing CRD1 was enhanced significantly in the T271I and Delta2N Envs. Histograms display the mean +/-SE (n = 3), arrows show P-values, t-test. C.) Syncytium formation in AH927-FX4P cells expressing feline CD134 (CD134), or feline CD134 CRD1/human CD134 chimera (CRD1). Cells were transfected with eukaryotic expression vectors bearing the GL8 or CPG41 envs carrying the WT, T271I, N342Y or Delta2N sequences. Cells were fixed and stained at 48 hours post-transfection, representative fields are shown.
###end p 38
###begin p 39
###xml 572 574 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1005 1007 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 1012 1014 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 841 844 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 846 849 <span type="species:ncbi:11673?1.0">FIV</span>
If the T271I mutation conferred enhanced usage of the CRD1 chimera as a receptor then we would predict that direct transfection of the T271I mutant into AH927-FX4P cells expressing the CRD1 chimera would result in enhanced syncytium formation compared to the wild type. We therefore compared the ability of the GL8 and CPG41 WT, T271I, N342Y and Delta2N Envs to induce syncytium formation in AH927 cells expressing CD134, the CRD1 chimera or vector only. Introduction of the T271I mutation enhanced syncytia formation in both CD134 and CRD1 chimera expressing cells (Fig. 3C). Few syncytia were observed in the CRD1 chimera-expressing cells transfected with GL8 or CPG41 WT Envs. The N342Y Envs induced fewer, and smaller syncytia in CD134-expressing cells than the WT Envs and few syncytia in the CRD1-expressing cells. Surprisingly, while HIV (FIV) pseudotypes bearing the GL8 and CPG41 Delta2N Envs behaved essentially the same as the pseudotypes bearing the T271I mutant Envs in the entry assay (Fig. 3A and 3B), in the syncytial assay, the Delta2N mutant Envs showed a marked reduction in syncytia formation compared with the T271I mutants. Similar results were observed with both the GL8 and CPG41 series of Envs indicating that in the presence of the N342Y mutation the enhancement of syncytium formation conferred by T271I was lessened. Neither the wild type nor the mutant Envs induced syncytium formation in the vector-only control cells (not shown). The data suggest that the potential N-linked glycosylation sites at positions 269 (NNT) and 342 (NTS) impact on the interaction between the viral Env and its receptor(s).
###end p 39
###begin title 40
Effect of glycosylation site ablation on sensitivity to CXCR4 antagonist
###end title 40
###begin p 41
###xml 598 599 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 1227 1233 1226 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
###xml 126 129 <span type="species:ncbi:11673?1.0">FIV</span>
The enhanced usage of the CD134-CRD1 chimaera by the T271 mutants may have arisen due to a less stringent interaction between FIV Env and CD134, the N-linked glycosylation site at 269 contributing to the receptor binding surface. Alternatively, removal of the N-linked glycosylation may have enhanced the ability of the Env to interact with CXCR4, either facilitating partial CD134-independent entry or by enhancing the affinity for CXCR4. To address the latter possibility, we examined the sensitivity of viral pseudotypes bearing the WT, T271I or N342Y Envs to the CXCR4 antagonist AMD3100 (Fig. 4). Sensitivity to AMD3100 was assessed on MYA-1 T cells (expressing low levels of CXCR4 [82]) and CLL-CD134 (expressing high levels of CXCR4 (Willett et al., unpublished data). Where CXCR4 was limiting (MYA-1 cells), infection with both GL8 and CPG41 was inhibited efficiently by AMD3100. Neither the T271 nor the N342Y mutation enhanced or reduced sensitivity to AMD3100 although it was notable that GL8 was significantly more sensitive to antagonism by AMD3100 than CPG41 (at 0.1 mug/ml AMD3100 there was a 100-fold reduction in GL8 entry compared with 5-fold for CPG41), suggesting that CPG41 has a higher affinity for CXCR4 per se. Where CXCR4 was abundant (CLL-CD134), inhibition of infection required significantly higher concentrations of AMD3100 and even at 10 mug/ml antagonist, the degree of inhibition never exceeded 80%. The data suggest that the T271I and N342Y mutations do not alter the affinity of the CXCR4 interaction significantly.
###end p 41
###begin p 42
###xml 102 105 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 107 110 <span type="species:ncbi:11673?1.0">FIV</span>
Sensitivity of glycosylation mutants to CXCR4 antagonist. Infection of MYA-1 and CLL-CD134 cells with HIV (FIV) pseudotypes bearing WT, T271I or N342Y mutant GL8 and CPG41 Envs was quantified in the presence of increasing concentrations of CXCR4 antagonist AMD3100. Infection is expressed as luciferase activity (CPM) and percent infection relative to control (no antagonist). Each point represents the mean +/- SE of triplicate samples.
###end p 42
###begin title 43
T271I does not induce CD134-independence
###end title 43
###begin p 44
###xml 462 463 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 790 791 786 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1026 1030 1022 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A,B</xref>
###xml 1105 1109 1101 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C,D</xref>
###xml 1171 1175 1167 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5E,F</xref>
###xml 1589 1593 1581 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A,B</xref>
###xml 1712 1716 1704 1708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C,D</xref>
###xml 1754 1758 1746 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5E,F</xref>
###xml 2015 2017 2003 2005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 2018 2020 2006 2008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 321 326 <span type="species:ncbi:9606">human</span>
###xml 524 529 <span type="species:ncbi:9606">human</span>
###xml 538 543 <span type="species:ncbi:9606">human</span>
###xml 641 644 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 645 648 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1410 1415 <span type="species:ncbi:9606">human</span>
###xml 2254 2257 <span type="species:ncbi:11673?1.0">FIV</span>
We next asked whether the T271I or N342Y mutations conferred CD134-independence upon the GL8 and CPG41 Envs. Feline AH927 cells stably transduced with vectors encoding feline CD134 or the CRD1 chimaera, or the empty expression vector (pDONAI) only, were transduced for a second time with vectors encoding feline CXCR4 or human CXCR4, or expression vector (pBabePuro only). Stable lines were selected that expressed either low level endogenous feline CXCR4 (Fig. 5, endog.)), high level feline CXCR4 (+feline), or high level human CXCR4 (+human) in conjunction with either the CRD1 chimaera or native CD134. The cells were then infected with HIV(FIV) luciferase pseudotypes bearing the GL8 and CPG41 Envs (wild type (WT), T271I, N342Y or Delta2N double mutant) and infectivity assayed (Fig. 5). If the T271I or N342Y mutations conferred CD134-independence, enhanced CXCR4 expression alone would be sufficient to promote viral entry. Control cells expressing endogenous CXCR4 were refractory to infection with all viruses (Fig. 5A,B, "endog.") and ectopic expression of CRD1 did not enhance infection (Fig. 5C,D, "endog."). In contrast, ectopic expression of feCD134 (Fig. 5E,F, "endog.") enhanced infection of the control with all viruses (>10-fold) suggesting that sufficient endogenous CXCR4 is present to facilitate viral entry in the presence of native primary receptor. The addition of exogenous feline or human CXCR4 alone did not enhance infection of the control cells mediated by either the GL8 or CPG41 Envs significantly, irrespective of whether WT, T271I, N342Y or Delta2N (Fig. 5A,B, control). In contrast, the addition of exogenous CXCR4 in the presence of either the feline CD134 CRD1 chimera (Fig. 5C,D, CRD1), or native feline CD134 (Fig. 5E,F, CD134) revealed a significantly more marked enhancement of infection with the T271I and Delta2N viruses than with the WT or N342Y viruses. The data are consistent with the T271I mutation removing the requirement of the viral Env for determinants in CRD2 [30,63], and thus improving its ability to utilise the CRD1 chimaera as an effective viral receptor. Accordingly, the data suggest that the N-linked glycosylation site ablated by the T271I mutation either contributes to the binding site on FIV Env for CD134, or constrains the conformation of Env such that it may only interact with native feline CD134.
###end p 44
###begin p 45
###xml 190 195 <span type="species:ncbi:9606">human</span>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 357 360 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 361 364 <span type="species:ncbi:11673?1.0">FIV</span>
Effect of ectopic CXCR4 expression on infection with glycosylation mutants. AH927 cells expressing low level endogenous CXCR4 (endog.) or enhanced levels of either feline CXCR4 (+feline) or human CXCR4 (+human), in conjunction with feline CD134 (feCD134), CRD1 of fCD134 in the context of hCD134 (CRD1), or vector-only control (Control), were infected with HIV(FIV) pseudotypes bearing the GL8 or CPG41 Envs. 72 hours post-infection luciferase activity was assayed. Each point represents the mean +/- SE of triplicate samples.
###end p 45
###begin title 46
Binding of soluble Fc-SU fusion proteins to CD134-expressing cells
###end title 46
###begin p 47
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 1387 1389 1387 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1546 1548 1546 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 2226 2228 2226 2228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 2440 2442 2440 2442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 2443 2445 2443 2445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 55 58 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1290 1295 <span type="species:ncbi:9606">human</span>
###xml 1373 1378 <span type="species:ncbi:9606">human</span>
###xml 1500 1505 <span type="species:ncbi:9606">human</span>
###xml 1647 1652 <span type="species:ncbi:9606">human</span>
###xml 1865 1870 <span type="species:ncbi:9606">human</span>
###xml 1907 1912 <span type="species:ncbi:9606">human</span>
###xml 2427 2430 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 2435 2438 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Previous studies have demonstrated that soluble IgG-Fc-FIV SU fusion proteins (Fc-SU) recapitulate the receptor binding specificity of the parent virus [29,83-85]. We therefore asked whether GL8 Fc-SU fusion proteins (proteins that exist primarily as dimers) derived from the WT, T271I or N342Y Envs (trimeric on the native virions) would display the receptor binding properties of their respective parent viruses. WT, T271I or N342Y GL8 Env Fc-SUs bound to feline CD134 expressing MCC cells (Fig. 6A, row 1) but not to control MCC cells (Fig. 6A, row 4), consistent with the usage of feline CD134 as a receptor on MCC cells (Fig. 3B). However, a similar level of binding was detected to cells expressing only CRD1 of feline CD134 (Fig. 6A, row 2) suggesting that when the Envs were expressed in soluble form as Fc-SU fusion proteins, the requirement for determinants in CRD2 of CD134 for receptor binding is lost. These data would suggest that the specificity of receptor binding of the GL8 Env may be dependent on intermolecular interactions in the tertiary complex of the native trimeric Env on virions and accordingly that the T271I mutation modulates this interaction. As an additional control for binding specificity, we assessed the binding of Fc-SU proteins to MCC cells expressing human CD134. Neither the WT nor the T271I and N342Y Envs support infection through human CD134 ([30] and data not shown), however, significant (albeit weak) binding of the WT, T271I and N342Y Fc-SU proteins to human CD134-expressing MCC was detected (Fig. 6A, row 3). It was notable that the MCC-derived cell lines transduced with the feline CD134, CRD1 or human CD134 expression vectors showed up-regulated expression of CXCR4 (48.5%, 63.1% and 87.6% respectively) relative to vector-only control cells (14.8%) indicating that the low level binding of the Fc-SU proteins to human CD134 may not have been mediated by human CD134, rather it could have reflected the marked up-regulation of endogenous CXCR4 on these cells. Accordingly, when we repeated the binding of WT Fc-SU to the four cell lines following pre-treatment of the cells with the CXCR4 antagonist AMD3100 and in the presence of anti-CXCR4 monoclonal antibody 44701 (Fig. 6B.), the low level of background binding of Fc-SU to CXCR4 was reduced from 17.2% to 2.6%, consistent with a direct interaction between the soluble SU and CXCR4, as has been noted previously for both FIV and HIV [82,86]. Given that CXCR4 expression alone does not confer susceptibility to infection with WT GL8, and that WT GL8 does not infect cells expressing CRD1 alone, these data suggest that the Fc-SU fusion proteins are in a distinct conformation that fails to mimic that found on native virions.
###end p 47
###begin p 48
###xml 11 14 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 206 211 <span type="species:ncbi:9606">human</span>
###xml 219 224 <span type="species:ncbi:9606">Human</span>
###xml 404 409 <span type="species:ncbi:9606">human</span>
###xml 550 555 <span type="species:ncbi:10090">mouse</span>
###xml 612 617 <span type="species:ncbi:9606">human</span>
###xml 796 801 <span type="species:ncbi:9606">human</span>
Binding of FIV Fc-SU fusion proteins to CD134-expressing cells. (A) MCC cells stably-transduced with retroviral vectors encoding full-length fCD134 (Feline), CRD1 of fCD134 in the context of hCD134 (CRD1), human CD134 (Human) or vector only control (CON) were incubated with Fc-SU fusion proteins derived from GL8 WT or glycosylation site mutants T271I and N342Y and bound protein detected using PE-anti-human IgG Fc by flow cytometry. CXCR4 and CD134 expression were assayed using anti-CXCR4 (44701) and CD134 (7D6) respectively followed by PE-anti-mouse IgG. (B) Inhibition of residual WT GL8 Fc-SU binding to human CD134 expressing cells by anti-CXCR4. Cells were pre-incubated with AMD3100 and 44701 prior to binding of WT Fc-SU and detection of bound protein by flow cytometry using PE-anti-human IgG Fc. Histograms show 10,000 events and are representative of at least two independent experiments.
###end p 48
###begin title 49
Effect of the T271I and N342Y mutations on sensitivity to virus neutralising antibody
###end title 49
###begin p 50
###xml 203 211 203 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 394 401 394 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 850 851 846 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 945 946 941 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 129 132 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 535 538 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 539 542 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 641 645 <span type="species:ncbi:9685">cats</span>
The predicted N-linked glycosylation sites ablated by the T271I and N342Y mutations are highly conserved among field isolates of FIV and reinstated rapidly (as early as 1 month post-infection) following in vivo replication of mutant virus [87]. These data suggest that the predicted N-link glycosylation sites at N269 and N342 are critical for maintaining the replicative capacity of the virus in vivo. It is possible that glycosylation at these sites protects the virus from virus neutralising antibody (VNA), thus the sensitivity of HIV(FIV) pseudotypes bearing the wild type GL8 Env or the T271I, N342Y and Delta2N mutants to sera from 8 cats infected with GL8 (4 years post-infection) was compared. Of the 8 sera evaluated, 5 sera (Q251, Q253, Q254, Q255 and Q256) contained potent virus neutralising activity (>90% neutralisation at 1/100, Fig. 7) while more modest neutralising activity was detected in sera from Q252, Q257 and Q258 (Fig. 7). There was no consistent difference in sensitivity to VNA between the WT and the T271I, N342Y and Delta2N mutants, suggesting that this region is not a major target for the humoral response to wild type virus.
###end p 50
###begin p 51
###xml 90 93 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 95 98 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 242 246 <span type="species:ncbi:9685">cats</span>
Sensitivity of GL8 WT and T271, N342Y and Delta2N mutants to virus neutralising antibody. HIV (FIV) pseudotypes bearing the WT, T271, N342Y or Delta2N Envs were incubated with 1/100, 1/1000 or 1/10,000 dilutions of plasma from 8 GL8-infected cats (Q251-258), or a no plasma negative control (neg), and plated onto CLL-CD134 cells. Luciferase activity was assayed at 72 hrs post-infection. (A) Luciferase activity (counts per minute), each point represents the mean of three replicates +/- SE, (B) Percent neutralisation relative to no plasma control.
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 47 56 47 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1004 1013 1004 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1014 1016 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1020 1022 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 1374 1376 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1377 1379 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1380 1382 1380 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1383 1385 1383 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 1386 1388 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 1906 1908 1906 1908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1909 1911 1909 1911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1912 1914 1912 1914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
###xml 2599 2601 2599 2601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 2723 2725 2723 2725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 2845 2847 2845 2847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 3125 3127 3125 3127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 3322 3324 3322 3324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B92">92</xref>
###xml 3427 3429 3427 3429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B92">92</xref>
###xml 18 21 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 107 111 <span type="species:ncbi:9685">cats</span>
###xml 149 152 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 249 252 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 389 392 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 448 451 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 471 474 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 747 750 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 891 894 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 899 902 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1266 1269 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1476 1479 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1638 1641 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 2207 2210 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 2437 2442 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2783 2786 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 3192 3197 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3228 3231 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The FL4 strain of FIV was derived by long-term in vitro culture of mixed peripheral blood lymphocytes from cats infected with the Petaluma strain of FIV [68]. The IL-2-independent cell line (FL4) derived from this mixed cell culture stably produced FIV particles at a high level that, following concentration and paraformaldehyde inactivation, provided the first effective vaccine against FIV infection [37], and the basis for the first commercial FIV vaccine, Fel-O-Vax FIV. The FL4 Env would appear to be both stable in its attachment to the viral particle during purification, and highly immunogenic. Here we show that the FL4 virus lacks predicted sites for N-linked glycosylation that are highly conserved in the majority of field strains of FIV. The location of these mutations, T271I and N342Y, is strikingly similar to previously described N-linked glycosylation sites in the Env of SIV and HIV that may contribute to enhanced immunogenicity of Env-based immunogens and an altered receptor usage in vitro [12,25,26,88]. Given the conservation of these sites in field strains, we predicted that one or both of these mutations may contribute to the process of cell culture adaptation which previous studies have shown to result in an increase in charge of the FIV Env V3-loop homologue and utilisation of CXCR4 alone as a viral receptor (CD134-independent infection) [27,33,34,89,90]. When the T271I and N342Y mutations were introduced into two primary field strains of FIV (GL8 and CPG41), the T271I mutation was shown to have a significant modulatory effect on the way the virus interacts with CD134. The GL8 and CPG41 strains of FIV recognise a complex determinant on CD134 that is dependent on residues in both CRD1 and CRD2 of the molecule, while strains such as PPR and B2542 are able to infect cells using a minimal determinant in CRD1 alone, suggesting a less complex interaction with CD134 [30,63,84]. That the removal of a single site for N-linked glycosylation (T271I) is sufficient to switch both GL8 and CPG41 from a complex to a minimal interaction would suggest that the N-linked glycosylation site ablated by the T271I mutation either forms a component of the receptor binding face of FIV Env, or contributes to the tertiary/quaternary structure of the Env trimer such that the receptor binding face of Env is presented to the viral receptor in the correct configuration. These data are reminiscent of studies with HIV-1 ADA where removal of an N-linked glycosylation site at the base of the V1V2 stem (N197) facilitated CD4-independent infection of canine cells through CCR5 [12], an effect that was postulated to be mediated by repositioning of the V1V2 loops and exposure of the CCR5 binding site [12]. An N197D mutation in Env improved CXCR4 utilisation by HIV ADA-1 following co-receptor switching from CCR5 to CXCR4 [91]. The mutations in V3 that conferred CXCR4 usage upon the virus were in themselves deleterious; it has been suggested that by altering the flexibility of the V1V2 loop, the N197D mutation compensated for the mutations in V3 that facilitated switching from CCR5 to CXCR4 usage [91]. Mutation of glycosylation sites adjacent to the V1V2 loops of HIV-1 DH12, a dual-tropic strain of HIV, either reduced or abolished completely cell-cell fusion mediated by both CXCR4 and CCR5 [92], this effect appeared to result, in part, from a marked reduction in CD4 binding by the mutated Env [92].
###end p 53
###begin p 54
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B93">93</xref>
###xml 793 794 790 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 795 797 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B94">94</xref>
###xml 900 901 897 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1722 1724 1719 1721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1725 1727 1722 1724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1744 1746 1741 1743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B95">95</xref>
###xml 1759 1761 1756 1758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B96">96</xref>
###xml 1832 1840 1829 1837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 2418 2420 2415 2417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 2718 2725 2715 2722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 3107 3109 3104 3106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 3212 3214 3209 3211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 3408 3415 3405 3412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 58 61 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 204 209 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 665 668 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1160 1163 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 1442 1445 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 2766 2769 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 3018 3022 <span type="species:ncbi:9685">cats</span>
###xml 3172 3176 <span type="species:ncbi:9685">cats</span>
###xml 3206 3210 <span type="species:ncbi:9685">cats</span>
Several studies have demonstrated that the V1V2 region of HIV Env plays an important role in viral cell tropism and receptor binding [52-57]. For example, in early studies, mutations in the V1/V2 loop of HIV-1 HXBc2 were observed to reduce both CD4-binding capacity and syncytium formation [56] while subsequently, determinants in V1/V2 were found to contribute to CCR3 usage in that substitution of the V1/V2 loop of the dual-tropic (R3/R5) strain ADA into the R5 strain BaL rendered the Env dual-tropic [93]. Solution of the crystal structure of the deglycosylated gp120 core in complex with CD4 and antibody 17b indicated that the stem of the V1 and V2 loops of HIV Env contributes to the "bridging sheet", a four-stranded anti-parallel beta-sheet that mediates chemokine receptor binding [7,94]. Binding of CD4 is thought to reposition the V1V2 loop stem (the V1V2 loop stem itself contacts CD4 [7]), facilitating the formation of the bridging sheet structure and subsequently permitting chemokine receptor binding. Thus modifications to the structure of the V1V2 loop may mimic CD4-binding and facilitate chemokine receptor binding. The T271I mutation in FIV Env may have a similar function; either by altering directly a contact point with CD134 or by facilitating CD134-independent infection. In this study, we found that the T271I mutation did not confer CD134-independent infection, rather it modulated usage of CD134 by the primary FIV Envs, reducing the requirement for residues in CRD2 of CD134 for viral entry and syncytium formation. A similar mode of interaction with CD134 has been described for the PPR and B2542 strains of virus, both of which are able to readily infect cells using CRD1 of CD134 alone [30,63]. Both the PPR [95] and B2542 [96] are capable of inducing immunological and neurological abnormalities in vivo that are consistent with immunodeficiency-causing lentiviruses, thus the ability of viruses to infect cells using CRD1 of CD134 alone is not in itself, debilitating to viral replication. It is possible that the nature of the interaction between the viral Env and CD134 changes with disease progression, in early infection viruses employ a high affinity complex interaction involving determinants in both CRD1 and CRD2 and in doing so may protect the virus from neutralising antibody or endogenous CD134-ligand (infection with PPR and B2542 is sensitive to modulation by CD134L [28]). As disease progresses, the Env-CD134 interaction may become less stringent, allowing the virus to expand more readily into CD134-negative cellular compartments through direct interactions with CXCR4. If N-linked glycosylation at N-269 contributes to the complexity of the Env-CD134 interaction in vivo, we would predict that late isolates of FIV would be more likely to harbour viral variants bearing mutations such as the T271I observed in FL4. Conversely, in early infection, viral variants bearing T271 would be suppressed. This hypothesis has been tested to some extent in a study in which cats were infected with the FL4 strain and virus re-isolated three years post infection [87]. Sequence analysis revealed an I271T reversion in 2 out of 3 cats and Y342N mutation in 3 of 3 cats [87], suggesting a strong selective pressure in favour of either reinstating the N-linked glycosylation sites following infection or suppressing the replication of T271I and Y342N bearing variants in vivo.
###end p 54
###begin p 55
###xml 238 245 238 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 104 108 <span type="species:ncbi:9685">cats</span>
###xml 325 328 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 363 366 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 415 418 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 469 472 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 580 583 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 643 646 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 651 654 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 916 919 <span type="species:ncbi:11673?1.0">FIV</span>
Neither the T271 nor the N342Y mutations affected the sensitivity of GL8 to neutralisation by sera from cats infected with the biological isolate of GL8, suggesting that this region may not be a primary target for neutralising antibodies in vivo. The N-linked glycosylation sites affected by the T271I and N342Y mutations in FIV lie in a predicted loop domain of FIV Env [76] that is analogous to the V1/V2 loop of HIV in schematic structural models [75]. V1 and V2 of FIV Env were originally assigned to hypervariable regions located in the leader and signal sequence regions of FIV Env [76], however, to facilitate ready comparisons between FIV and HIV we refer to the region between amino acids 248 and 354 as the V1/V2 homologue. The conservation of this region amongst viral strains is consistent with the region not being under a strong selective pressure from the host immune system. However as the Fel-O-Vax FIV vaccine is derived from FL4 virus bearing the T271I and N342Y mutations, it is possible that deglycosylation of this region in the vaccine strain may render the region immunogenic for vaccinates and contribute to protection from challenge.
###end p 55
###begin p 56
###xml 96 99 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 444 447 <span type="species:ncbi:11673?1.0">FIV</span>
In conclusion, we have shown that a single glycosylation site ablated in V1V2-loop homologue of FIV modulates the Env-CD134 interaction. As this glycosylation site is ablated in the FL4 vaccine strain, future studies should address whether antibodies induced by vaccination with immunogens bearing this mutation target this region of the Env and whether selective deglycosylation of this region may offer a strategy for the rationale design of FIV vaccines.
###end p 56
###begin title 57
Competing interests
###end title 57
###begin p 58
The authors declare that they have no competing interests.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
EM and NL performed the DNA manipulations, cell culture, viral pseudotype preparation and biochemical analyses. AS carried out the virus neutralisation assays. BW purified mutant viruses and performed flow cytometric assays. MH and BW designed the experiments and wrote the manuscript. All authors read and approved the final manuscript.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
This work was supported by Public Health Service grant AI049765 to BW & MH from the National Institute of Allergy and Infectious Diseases.
###end p 62
###begin article-title 63
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
###end article-title 63
###begin article-title 64
###xml 53 58 <span type="species:ncbi:9606">human</span>
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
###end article-title 64
###begin article-title 65
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chemokine receptors as HIV-1 coreceptors:Roles in viral entry, tropism, and disease.
###end article-title 65
###begin article-title 66
Cell surface receptors, virus entry and tropism of primate lentiviruses
###end article-title 66
###begin article-title 67
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 146 181 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
###end article-title 67
###begin article-title 68
###xml 6 11 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Broad HIV-1 neutralization mediated by CD4-binding site antibodies
###end article-title 68
###begin article-title 69
###xml 16 19 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 100 105 <span type="species:ncbi:9606">human</span>
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
###end article-title 69
###begin article-title 70
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The antigenic structure of the HIV gp120 envelope glycoprotein
###end article-title 70
###begin article-title 71
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
###end article-title 71
###begin article-title 72
###xml 49 52 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Antigenic conservation and immunogenicity of the HIV coreceptor binding site
###end article-title 72
###begin article-title 73
###xml 56 84 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants
###end article-title 73
###begin article-title 74
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops
###end article-title 74
###begin article-title 75
###xml 29 34 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
CD4-independent infection by HIV-2 is mediated by fusin.
###end article-title 75
###begin article-title 76
###xml 29 32 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 37 40 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo
###end article-title 76
###begin article-title 77
###xml 36 71 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication
###end article-title 77
###begin article-title 78
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein
###end article-title 78
###begin article-title 79
###xml 111 146 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 populations in blood and breast milk are similar
###end article-title 80
###begin article-title 81
###xml 34 39 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
CD4-dependent and CD4-independent HIV-2: consequences for neutralization
###end article-title 81
###begin article-title 82
###xml 98 127 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain
###end article-title 82
###begin article-title 83
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor
###end article-title 83
###begin article-title 84
###xml 129 164 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate
###end article-title 84
###begin article-title 85
###xml 29 32 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Immune escape and tropism of HIV
###end article-title 85
###begin article-title 86
###xml 40 68 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Change in tropism upon immune escape by human immunodeficiency virus
###end article-title 86
###begin article-title 87
###xml 82 117 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades
###end article-title 87
###begin article-title 88
###xml 20 49 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity
###end article-title 88
###begin article-title 89
###xml 42 71 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Use of CD134 as a primary receptor by the feline immunodeficiency virus
###end article-title 89
###begin article-title 90
###xml 36 65 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Probing the interaction between the feline immunodeficiency virus and CD134 using a novel monoclonal antibody 7D6 and CD134L (OX40L)
###end article-title 90
###begin article-title 91
###xml 0 29 <span type="species:ncbi:11673">Feline immunodeficiency virus</span>
Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor
###end article-title 91
###begin article-title 92
###xml 81 110 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
###xml 112 115 <span type="species:ncbi:11673?1.0">FIV</span>
Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus (FIV).
###end article-title 92
###begin article-title 93
###xml 48 77 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Nucleotide-sequence and genomic organization of feline immunodeficiency virus
###end article-title 93
###begin article-title 94
###xml 21 50 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Molecular cloning of feline immunodeficiency virus.
###end article-title 94
###begin article-title 95
Common mechanism of infection by lentiviruses.
###end article-title 95
###begin article-title 96
###xml 63 68 <span type="species:ncbi:9606">human</span>
Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses.
###end article-title 96
###begin article-title 97
###xml 67 96 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Factors that increase the effective concentration of CXCR4 dictate feline immunodeficiency virus tropism and kinetics of replication
###end article-title 97
###begin article-title 98
###xml 41 54 <span type="species:ncbi:9685">domestic cats</span>
Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency syndrome.
###end article-title 98
###begin article-title 99
###xml 79 108 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus.
###end article-title 99
###begin article-title 100
###xml 40 69 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Experimental vaccine protection against feline immunodeficiency virus
###end article-title 100
###begin article-title 101
###xml 0 29 <span type="species:ncbi:11673">Feline immunodeficiency virus</span>
Feline immunodeficiency virus vaccination:characterization of the immune correlates of protection.
###end article-title 101
###begin article-title 102
###xml 52 56 <span type="species:ncbi:9685">cats</span>
###xml 72 101 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Env-specific cytotoxic T lymphocytes predominate in cats protected from feline immunodeficiency virus infection by vaccination.
###end article-title 102
###begin article-title 103
###xml 84 113 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines.
###end article-title 103
###begin article-title 104
###xml 95 124 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Involvement of gag-specific and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
###end article-title 104
###begin article-title 105
###xml 35 64 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Limited efficacy of an inactivated feline immunodeficiency virus vaccine
###end article-title 105
###begin article-title 106
###xml 27 56 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Vaccine protection against feline immunodeficiency virus: setting the challenge
###end article-title 106
###begin article-title 107
###xml 49 78 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Suppression of virus burden by immunisation with feline immunodeficiency virus Env protein.
###end article-title 107
###begin article-title 108
###xml 18 47 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Enhancement after feline immunodeficiency virus vaccination.
###end article-title 108
###begin article-title 109
###xml 30 59 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection
###end article-title 109
###begin article-title 110
###xml 24 28 <span type="species:ncbi:9685">cats</span>
###xml 62 65 <span type="species:ncbi:11673?1.0">FIV</span>
Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells
###end article-title 110
###begin article-title 111
###xml 23 27 <span type="species:ncbi:9685">cats</span>
###xml 56 70 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 107 136 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Accelerated viremia in cats vaccinated with recombinant vaccinia virus expressing envelope glycoprotein of feline immunodeficiency virus
###end article-title 111
###begin article-title 112
###xml 15 44 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Enhancement of feline immunodeficiency virus infection after immunisation with envelope glycoprotein subunit vaccines.
###end article-title 112
###begin article-title 113
###xml 42 71 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts
###end article-title 113
###begin article-title 114
###xml 103 138 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120
###end article-title 114
###begin article-title 115
###xml 39 74 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization
###end article-title 115
###begin article-title 116
###xml 0 28 <span type="species:ncbi:12721">Human immunodeficiency virus</span>
Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread
###end article-title 116
###begin article-title 117
###xml 68 103 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding
###end article-title 117
###begin article-title 118
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody
###end article-title 118
###begin article-title 119
###xml 35 40 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Relation of phenotype evolution of HIV-1 to envelope V2 configuration
###end article-title 119
###begin article-title 120
###xml 82 111 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence.
###end article-title 120
###begin article-title 121
###xml 89 118 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Establishment of a feline T-lymphoblastoid cell line highly sensitive for replication of feline immunodeficiency virus
###end article-title 121
###begin article-title 122
A feline large granular lymphoma and its derived cell line
###end article-title 122
###begin article-title 123
###xml 67 83 <span type="species:ncbi:10665">bacteriophage T4</span>
Cleavage of structural proteins during the assembly of the head of bacteriophage T4
###end article-title 123
###begin article-title 124
###xml 25 29 <span type="species:ncbi:9685">cats</span>
###xml 33 62 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Serological responses of cats to feline immunodeficiency virus.
###end article-title 124
###begin article-title 125
###xml 58 87 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Mapping the domains of CD134 as a functional receptor for feline immunodeficiency virus
###end article-title 125
###begin article-title 126
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co- receptor.
###end article-title 126
###begin article-title 127
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 89 118 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication.
###end article-title 127
###begin article-title 128
###xml 59 88 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus
###end article-title 128
###begin article-title 129
Dissecting the regions of virion-associated Kaposi's sarcoma-associated herpesvirus complement control protein required for complement regulation and cell binding
###end article-title 129
###begin article-title 130
Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency viruses: importance for diagnostic reagents and vaccines
###end article-title 130
###begin article-title 131
###xml 46 75 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Comparison of two host cell range variants of feline immunodeficiency virus.
###end article-title 131
###begin article-title 132
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
###end article-title 132
###begin article-title 133
###xml 23 52 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Nucleotide sequence of feline immunodeficiency virus: classification of Japanese isolates into two subtypes which are distinct from non-Japanese subtypes
###end article-title 133
###begin article-title 134
###xml 13 16 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 36 39 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 85 88 <span type="species:ncbi:11673?1.0">FIV</span>
Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate
###end article-title 134
###begin article-title 135
###xml 29 64 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies
###end article-title 135
###begin article-title 136
Prediction of the secondary structure of proteins from their amino acid sequence
###end article-title 136
###begin article-title 137
###xml 121 149 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 193 208 <span type="species:ncbi:10029">Chinese hamster</span>
Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells
###end article-title 137
###begin article-title 138
###xml 28 57 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Structure and variations of feline immunodeficiency virus envelope glycoproteins.
###end article-title 138
###begin article-title 139
Embedding strategies for effective use of information from multiple sequence alignments
###end article-title 139
###begin article-title 140
###xml 55 83 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region
###end article-title 140
###begin article-title 141
###xml 29 64 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 140 145 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
###end article-title 141
###begin article-title 142
###xml 62 91 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Chemokine receptors and co-stimulatory molecules: Unravelling feline immunodeficiency virus infection
###end article-title 142
###begin article-title 143
###xml 134 163 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Upregulation of surface feline CXCR4 expression following ectopic expression of CCR5: implications for studies of the cell tropism of feline immunodeficiency virus
###end article-title 143
###begin article-title 144
###xml 14 43 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Modulation of feline immunodeficiency virus infection by stromal cell-derived factor (SDF-1).
###end article-title 144
###begin article-title 145
###xml 39 68 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
###xml 70 73 <span type="species:ncbi:11673?1.0">FIV</span>
###xml 100 103 <span type="species:ncbi:11673?1.0">FIV</span>
Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope
###end article-title 145
###begin article-title 146
###xml 67 96 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus
###end article-title 146
###begin article-title 147
###xml 23 52 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Binding of recombinant feline immunodeficiency virus surface glycoprotein to feline cells: role of CXCR4, cell-surface heparans, and an unidentified non-CXCR4 receptor
###end article-title 147
###begin article-title 148
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
CD4-independent association between HIV-1 gp120 and CXCR4: Functional chemokine receptors are expressed in human neurons
###end article-title 148
###begin article-title 149
###xml 64 93 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein
###end article-title 149
###begin article-title 150
###xml 39 74 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses
###end article-title 150
###begin article-title 151
###xml 17 46 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
A determinant of feline immunodeficiency virus involved in CrFK tropism.
###end article-title 151
###begin article-title 152
###xml 66 95 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
A single mutation within the V3 envelope neutralization domain of feline immunodeficiency virus determines its tropism for CRFK cells.
###end article-title 152
###begin article-title 153
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations
###end article-title 153
###begin article-title 154
###xml 93 128 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism
###end article-title 154
###begin article-title 155
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop
###end article-title 155
###begin article-title 156
###xml 12 15 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
###end article-title 156
###begin article-title 157
###xml 13 17 <span type="species:ncbi:9685">cats</span>
###xml 73 102 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Infection of cats with molecularly cloned and biological isolates of the feline immunodeficiency virus
###end article-title 157
###begin article-title 158
###xml 27 56 <span type="species:ncbi:11673">feline immunodeficiency virus</span>
Longitudinal assessment of feline immunodeficiency virus kinetics in plasma by use of a quantitative competitive reverse transcriptase PCR
###end article-title 158

